Method of treating arthritis with SERP-1 and an immunosuppressant
Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1/immunosuppressant combination admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.
1. A method of treating arthritis in diseased tissues of a mammalian subject corn pris ing administering to said subject a therapeutically effective amount of SERP-1, SERP-1 analog, or biologically active fragment thereof, and an immunosuppressant, wherein said SERP-1, SERP-1 analog, or biologically active fragment thereof acts synergistically with said immnunosuppressant to improve arthritic clinical score.
2. The method of claim 1 comprising administering to said subject a therapeutically effective amount of SERP-1.
3. The method claim 2 , wherein said SERP-1 comprises the sequence of SEQ ID NO: 1.
4. The method of claim 2 , wherein said SERP-1 comprises an amino acid sequence comprising the sequence set forth in SEQ ID NO: 1 with a substitution of any amino acid other than cysteine at position 244 of SEQ ID NO: 1.
5. The method of claim 1 comprising administering to said subject a therapeutically effective amount of biologically active fragment of SERP-1.
6. The method of any one of claims 2 , 3 , or 5 , wherein said immunosuppressant is cyclosporin A or PK506.
7. The method of any one of claims 2 , 3 , or 5 , wherein said mammalian subject is human.
8. The method of any one of claims 2 , 3 , or 5 , wherein said arthritis is rheumatoid arthritis.
9. The method of any one of claims 2 , 3 , or 5 , wherein said immunosuppressant is administered prior to administration of a therapeutically effective amount of said SERP-1 or said biologically active fragment or SERP-1.
10. The method of any one of claims 2 , 3 , or 5 , wherein said SERP-1 or said biologically active fragment of SERP-1 is delivered by intravenous, intra-arterial, intra-articular, subcutaneous, intraperitoneal, intraspinal, intrarectal, intramuscular infusion, or aerosol inhalant.